Restart Life Sciences Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NMLSF research report →
About the company
Restart Life Sciences Corp. , through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome.
- CEO
- Steve Loutskou
- IPO
- 2011
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $1.28M
- P/E
- -2.27
- P/S
- 23.09
- P/B
- 3.11
- EV/EBITDA
- -2.40
- Div Yield
- 0.00%
- Gross Margin
- -80.81%
- Op Margin
- -723.29%
- Net Margin
- -667.34%
- ROE
- -130.86%
- ROIC
- -51.29%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,390,538 · -718.72%
- EPS
- $-0.00 · -102.72%
- Op Income
- $-1,345,316
- FCF YoY
- -899.29%
- 52W High
- $0.12
- 52W Low
- $0.01
- 50D MA
- $0.06
- 200D MA
- $0.07
- Beta
- -0.80
- Avg Volume
- 901
Get TickerSpark's AI analysis on NMLSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NMLSF coverage
Recent articles, reports, and earnings notes.
No research on NMLSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NMLSF report →Similar companies
Peers in the same neighborhood.